PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 21, 2004

Primary Completion Date

April 1, 2018

Study Completion Date

May 31, 2018

Conditions
AdenocarcinomaColorectal CancerOvarian CancerBreast Cancer
Interventions
BIOLOGICAL

PANVAC-V

Patients receive 2 x 10(8) pfu PANVAC-V (vaccinia) subcutaneously on Day 1.

BIOLOGICAL

PANVAC-F

Patients receive 1 x 10(9) pfu PANVAC-F (fowlpox) or about days 15, 29, and 43 then every month for 12 doses then every 3 months until disease progression or toxicity.

DRUG

Sargramostim (GM-CSF, Leukine)

100g sargramostim will be given subcutaneously at the site of the vaccination on each vaccination day and for three consecutive days thereafter.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00088413 - PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | Biotech Hunter | Biotech Hunter